Plus Therapeutics Announces Key Trial Advances and Rollout Plans

Introduction

Plus Therapeutics, Inc. (Nasdaq: PSTV) is a Houston, Texas-based clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. The company utilizes proprietary nanoliposome and alginate microsphere technologies to encapsulate radioisotopes—primarily Rhenium-186 and Rhenium-188—to deliver localized doses of radiation directly to tumors while minimizing exposure to surrounding healthy tissue. As of July 8, 2025, PSTV shares traded on the NASDAQ at USD 0.3817, reflecting a 27.02% increase on a volume of 27,737,678 shares.

Ticker	Exchange	Price (USD)	Change (%)	Volume	Date
PSTV	NASDAQ	0.3817	+27.02	27,737,678	2025-07-08

Corporate Structure and Team

Founded in 2019 (formerly Cytori Therapeutics, Inc.), Plus Therapeutics employs between 11 and 50 professionals across research, clinical development, regulatory affairs, and corporate functions. The company is led by President & Chief Executive Officer Marc H. Hedrick, M.D., and supported by Chief Financial Officer and General Counsel Kyle Guse. Plus Therapeutics holds multiple patents for its BMEDA chelator technology used in the transport and retention of Rhenium radioisotopes within nanoliposomes.

Radiotherapeutics by Marcel Strauß

Developments and News

In alignment with the FDA’s Project Optimus, Plus Therapeutics initiated the ReSPECT-LM dose optimization trial for REYOBIQ™ (rhenium Re 186 obisbemeda) aimed at treating leptomeningeal metastases. This trial follows a Phase 1 single-dose escalation study that demonstrated the feasibility of intratumoral Rhenium delivery in patients with recurrent glioblastoma and pediatric brain cancers. The ReSPECT-LM trial is supported by a USD 17.6 million award from the Cancer Prevention and Research Institute of Texas, and aims to identify dosing regimens that optimize safety and efficacy.

Additionally, Plus Therapeutics announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC, plans to implement a U.S. commercial rollout in the second half of 2025 for a proprietary cerebrospinal fluid assay platform designed to detect central nervous system metastases.

On the corporate filings front, a Form S-1 registration statement filed on April 4 and amended on April 23, 2025, became effective on June 23, 2025. On the same date, the company filed a request to withdraw a Form S-3 registration, noting that no securities were sold under that statement and that any fees paid may be applied to future offerings. Two days later, on June 25, 2025, The Hewlett Fund LP amended its Schedule 13G/A filing to report zero shares and zero percent ownership of PSTV stock.

Financial and Strategic Analysis

Plus Therapeutics’ share price increase of 27.02% on July 8, 2025, alongside trading volume exceeding 27 million, suggests increased investor interest, likely influenced by clinical milestones in its ReSPECT-LM program and development towards a commercial diagnostic platform. The effectiveness of the S-1 registration statement indicates the company’s readiness for potential capital raises, while the withdrawal of the S-3 suggests a reevaluation of market conditions prior to any secondary offering. The absence of significant institutional ownership, as noted in the Schedule 13G/A, indicates the company's reliance on public and strategic financing to support its R&D and commercialization efforts.

Market Position and Industry Context

Plus Therapeutics operates within the radiopharmaceutical sector, where the precision delivery of therapeutic radioisotopes is essential for the treatment of solid tumors and metastases. Its nanoliposome-based platform aims to differentiate itself from competitors through localized radiation dosing with reduced systemic toxicity. REYOBIQ™ targets brain and central nervous system cancers—including recurrent glioblastoma, leptomeningeal metastases, and pediatric tumors—while a next-generation Rhenium-188 radioembolization therapy in development is focused on solid organ cancers such as hepatocellular carcinoma and metastatic colorectal cancer. The company’s patent portfolio and alignment with FDA dose-optimization initiatives position Plus Therapeutics within a specific segment of targeted oncology innovation.

tl;dr

As of July 8, 2025, PSTV shares were priced at USD 0.3817 (+27.02 %), associated with the ReSPECT-LM dose optimization trial for REYOBIQ™ and plans for CNSide Diagnostics’ U.S. commercial rollout in the second half of 2025. The S-1 registration statement became effective on June 23, 2025, while a concurrent S-3 withdrawal reflects a strategic pause on secondary offerings. Future developments will depend on trial outcomes, alignment with FDA initiatives under Project Optimus, and potential capital raises to support ongoing development and commercialization.